Patricia Bhatt

Patricia Bhatt has led clinical pharmacology efforts establishing flat (fixed) dosing for immune checkpoint inhibitors, demonstrating through population pharmacokinetic modeling that body-weight-based dosing of nivolumab and other monoclonal antibody immunotherapies provides no pharmacokinetic advantage over fixed dosing due to the shallow relationship between body weight and drug exposure. Her research showed that flat dosing simplifies clinical practice, reduces dosing errors, and minimizes drug waste without compromising efficacy or safety. She established population PK frameworks for immunotherapy dose selection that have been adopted across the industry. Her work has influenced regulatory approval of flat doses for multiple checkpoint inhibitors.